Thomas Cipolla
Medical · Lindenhurst, NYNPI 1992860282
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,153 of the $23,275 with a category attached, or 65.1%. 53 manufacturers reported payments, led by Intra-sana Laboratories at 35.1% of the total. Reporting peaked in 2023 at $8,090 and has fallen 71.6% since, to $2,301 in 2025. Among medical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 771 payments — averaging $30.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intra-sana Laboratories$8K
- AbbVie$2K
- AstraZeneca$2K
- Biohaven Pharmaceuticals, Inc.$2K
- Amgen$972
- Pfizer$772
- plus $8K from 47 others
What the payments were for
- Consulting fees$8003%
- Speaking & faculty fees$7,00030%
- Food & beverage$15,15365%
- Education$220%
- Gifts$3001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reltone 200 Mg$5,293
- Reltone 400 Mg$5,293
- GLYCATE$4,993
- NURTEC ODT$917
- GEMTESA$283
- OPZELURA$250
- Rinvoq$125
- Pogo Automatic Blood Glucose Monitoring System$124
How this compares
$23,275 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 205 | $372,889 |
| MounjaroTirzepatide | 118 | $136,399 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $75,861 |
| JardianceEmpagliflozin | 59 | $73,447 |
| EliquisApixaban | 53 | $68,722 |
| Zileuton ErZileuton | 22 | $66,470 |
| TrulicityDulaglutide | 38 | $63,234 |
| RybelsusSemaglutide | 24 | $55,660 |
| FarxigaDapagliflozin Propanediol | 35 | $50,568 |
| ProliaDenosumab | 28 | $48,379 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 14 | $41,596 |
| Ursodiol | 14 | $32,901 |
| Xigduo XrDapaglifloz Propaned/Metformin | 29 | $30,064 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $29,123 |
| Diclofenac Sodium | 28 | $27,643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $548 | $428,549229 claims |
| Lilly USA, LLCMounjaro, Trulicity | $524 | $199,633156 claims |
| Boehringer IngelheimJardiance, Synjardy | $772 | $97,12279 claims |
| PfizerEliquis, Nurtec Odt | $772 | $87,90664 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $771 | $86,54970 claims |
| AstraZenecaFarxiga, Airsupra | $1,820 | $63,22852 claims |
| AmgenProlia | $972 | $48,37928 claims |
| Intra-sana LaboratoriesReltone | $8,169 | $25,90417 claims |
| AbbVieLinzess, Synthroid | $2,018 | $21,47987 claims |
| Johnson & JohnsonXarelto | $138 | $19,97816 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $241 | $11,07122 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $49 | $5,262325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.
Other medical in Lindenhurst
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.